Success Metrics

Clinical Success Rate
100.0%

Based on 9 completed trials

Completion Rate
100%(9/9)
Active Trials
0(0%)
Results Posted
56%(5 trials)

Phase Distribution

Ph not_applicable
1
10%
Ph phase_1
1
10%
Ph phase_2
2
20%
Ph phase_3
2
20%
Ph phase_4
4
40%

Phase Distribution

1

Early Stage

2

Mid Stage

6

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
1(10.0%)
Phase 2Efficacy & side effects
2(20.0%)
Phase 3Large-scale testing
2(20.0%)
Phase 4Post-market surveillance
4(40.0%)
N/ANon-phased studies
1(10.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

9 of 9 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

10

all time

Status Distribution
Completed(9)
Other(1)

Detailed Status

Completed9
unknown1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (10.0%)
Phase 22 (20.0%)
Phase 32 (20.0%)
Phase 44 (40.0%)
N/A1 (10.0%)

Trials by Status

completed990%
unknown110%

Recent Activity

0 active trials
Showing 5 of 10
completedphase_4

Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to <2 Years (MK-8616-169)

NCT03909165
completedphase_3

Recovery From dNMB Using Different Sugammadex Doses in Elderly Patients Undergoing Robot-assisted Prostatectomy

NCT04854993
completedphase_2

Dose Finding Study for Effective Reversal of a Deep Rocuronium-induced Neuromuscular Block With Sugammadex in Morbidly Obese Patients

NCT01911520
completedphase_4

Efficacy, Safety, and Pharmacokinetics of Sugammadex for Reversal of Neuromuscular Blockade (NMB) in Pediatric Participants (MK-8616-089)

NCT03351608
completedphase_4

Safety of Sugammadex for the Reversal of Neuromuscular Blockade in American Society of Anesthesiologists (ASA) Class 3 or 4 Participants (MK-8616-145)

NCT03346057
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT03909165Phase 4

Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to <2 Years (MK-8616-169)

Completed
NCT04854993Phase 3

Recovery From dNMB Using Different Sugammadex Doses in Elderly Patients Undergoing Robot-assisted Prostatectomy

Completed
NCT01911520Phase 2

Dose Finding Study for Effective Reversal of a Deep Rocuronium-induced Neuromuscular Block With Sugammadex in Morbidly Obese Patients

Completed
NCT03351608Phase 4

Efficacy, Safety, and Pharmacokinetics of Sugammadex for Reversal of Neuromuscular Blockade (NMB) in Pediatric Participants (MK-8616-089)

Completed
NCT03346057Phase 4

Safety of Sugammadex for the Reversal of Neuromuscular Blockade in American Society of Anesthesiologists (ASA) Class 3 or 4 Participants (MK-8616-145)

Completed
NCT00988065Phase 1

Sugammadex Hypersensitivity Study (Study P06042)

Completed
NCT00421148Phase 3

Dose-Finding Pediatric and Adult Trial With Sugammadex (Org 25969, MK-8616, SCH 900616) (19.4.306) (MK-8616-034) (P05961)

Completed
NCT02545595Phase 2

Sugammadex Dosage Based on Ideal Body Weight for Profound Rocuronium-induced Neuromuscular Blockade Reversal in Morbidly Obese Patients

Completed
NCT01785758Phase 4

Efficacy and Safety of Sugammadex in Renal Diseased Patients

Completed
NCT01301261Not Applicable

Sugammadex: Effect on the Awareness Monitoring and Hemodynamics

Unknown

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10